Nektar Therapeutics

Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Company growth
Type
Public
HQ
San Francisco, US
Founded
1990
Size (employees)
623 (est)+2%
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US

Key People at Nektar Therapeutics

Robert Chess

Robert Chess

Chairman of the Board
Jillian B. Thomsen

Jillian B. Thomsen

Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth

Dorian Hirth

Senior Vice President, Human Resources and Facilities Operations
Timothy A. Riley

Timothy A. Riley

Senior Vice President, Technology Assessment and Quality Assurance
Purnanand D. Sarma

Purnanand D. Sarma

Vice President of Pharmaceutical Development

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Hyderabad, Huntsville
San Francisco, US
Hyderabad, IN
Huntsville, US

Nektar Therapeutics Metrics

Nektar Therapeutics Summary

Market capitalization

$2.06 B

Closing share price

$13.2
Nektar Therapeutics's current market capitalization is $2.06 B.

Nektar Therapeutics Financials

Nektar Therapeutics's revenue is $201 M in FY, 2014 which is 34.77% increase from the previous period.
FY, 2014FY, 2013

Revenue

$201 M$149 M

Revenue growth, %

34.8%

Gross profit

$172 M$110 M

Operating income

$-16.5 M$-120 M

Operating expense total

$189 M$231 M

Net Income

$-53.9 M$-162 M

Operating cash flow

$-26.7 M$13.6 M

Nektar Therapeutics Market Value History

Nektar Therapeutics Online Presence

Nektar Therapeutics Company Life

You may also be interested in